Get the Stockscreener App
1.32
7.04%
-0.10
After Hours:
1.40
0.08
+6.06%
Phio Pharmaceuticals Corp stock is traded at $1.32, with a volume of 140.96K.
It is down -7.04% in the last 24 hours and down -35.29% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$1.42
Open:
$1.4
24h Volume:
140.96K
Relative Volume:
0.02
Market Cap:
$6.59M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.1618
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-15.92%
1M Performance:
-35.29%
6M Performance:
-50.00%
1Y Performance:
-84.69%
1-Day Range:
$1.31
$1.43
1-Week Range:
$1.31
$1.61
52-Week Range:
$1.31
$10.35
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.32 | 6.59M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Can Phio's Novel siRNA Cancer Technology Impress Investors at Upcoming Roadshow? - StockTitan
PHIO stock touches 52-week low at $1.48 amid market challenges - Investing.com
PHIO stock touches 52-week low at $1.48 amid market challenges By Investing.com - Investing.com South Africa
Brokers Offer Predictions for PHIO FY2024 Earnings - Defense World
Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals Appoints David Deming to Board - TipRanks
Phio Pharmaceuticals expands board with new director By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals Corp. Appoints David H. Deming to Board of Directors -February 20, 2025 at 09:54 am EST - Marketscreener.com
H.C. Wainwright maintains Buy rating, $4 target on Phio Pharma stock - Investing.com
Phio Pharmaceuticals expands board with new director - Investing.com
Healthcare Finance Veteran With 30-Year Wall Street Track Record Takes Seat on Phio's BoardHere's Why It Matters - StockTitan
Phio Pharmaceuticals (NASDAQ:PHIO) Given “Buy” Rating at HC Wainwright - Defense World
PHIO Stock: The Biotech Breakthrough You Can't Ignore! Is This the Future of Immunotherapy? - Elblog.pl
Reviewing BridgeBio Pharma (NASDAQ:BBIO) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals (NASDAQ:PHIO) Shares Down 5.8% – Should You Sell? - Defense World
Phio Pharma (NASDAQ:PHIO) Stock Quotes, Forecast and News Summary - Benzinga
Inside Phio's Revolutionary siRNA Cancer Treatment: CEO Reveals Clinical Progress - StockTitan
Revolutionary Cancer Treatment or Environmental Savior? - Elblog.pl
Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis - MarketBeat
Phio Pharmaceuticals CEO to Present Breakthrough Cancer Treatment at Renmark Virtual Roadshow - StockTitan
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Newsfile
Phio Pharmaceuticals Secures $1.83M Direct Offering to Advance Cancer Treatment Pipeline - StockTitan
We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run - MSN
Phio Pharmaceuticals Raises $1.83M in Direct Offering with Warrant Coverage at $3.00/Share - StockTitan
Stock market news: Phio Pharmaceuticals +50.19%, DatChat +46.01% among top gainers during mid day trading - Business Upturn
Stock market today: Phio Pharmaceuticals -20.76%, Soligenix -20.15% among biggest losers in early trading - Business Upturn
Phio Pharmaceuticals Raises $2.5M Through Direct Offering at $3.00 Per Share - StockTitan
Phio Pharmaceuticals sharply lower on equity offering - MSN
Stock market news: Phio Pharmaceuticals -50.61%, Salarius Pharmaceuticals -28.61% among biggest losers during mid day trading - Business Upturn
Stock market news: Eterna Therapeutics posted gain of 100.87% while Phio Pharmaceuticals saw loss of 50.44% during mid day trading - Business Upturn
What's Going On With Phio Pharmaceuticals Stock Today? - Benzinga
Stock market today: Phio Pharmaceuticals -41.48%, Aehr Test Systems -26.86% among biggest losers in early trading - Business Upturn
Stock market today: Eterna Therapeutics gain over 136.63% while Phio Pharmaceuticals plunged by 40.25% in early trading - Business Upturn
Nasdaq Jumps 150 Points; US Producer Prices Increase 0.2% In December - Benzinga
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Newsfile
Phio stock surged 330%: Phio reports 100% tumor clearance - Markets.com
Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. … more inside - newschannelnebraska.com
Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated - MSN
Phio Pharmaceuticals skyrockets on skin cancer drug trial success - Mugglehead
Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. ... more inside - openPR
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge - Benzinga
Unlocking the Surge! Phio Pharmaceuticals Surprises Everyone with 300% Stock Surge - Elblog.pl
Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On MondayHere's Why - Benzinga
Stock market news: Phio Pharmaceuticals +296.88%, Salarius Pharmaceuticals +153.67% among top gainers during mid day trading - Business Upturn
Stock market news: Shallgo saw rise of 286.81% while Kairos Pharma was up by 176.47% during mid day trading - Business Upturn
Stocks to Watch in 2025: PHIO, LPTH, KAVL and more - Markets.com
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | President & CEO |
Jun 06 '24 |
Buy |
0.75 |
1,000 |
750 |
19,990 |
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):